Aridis Pharmaceuticals Other Liabilities

The latest other liabilities for ARDS is $12M as of September 2023. In the prior-year period, the figure was $0. Investors often review this figure alongside Aridis Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ARDS's other liabilities moved from $0 to $12M. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aridis Pharmaceuticals's operating scale or balance-sheet position.

A other liabilities figure of $12M for ARDS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ARDS's other liabilities ($12M), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Aridis Pharmaceuticals's other liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.